Clinical trials: Malaria Fever
Malaria
Kilimanjaro IPTi Drug Options Trial
Malaria and anaemia are major causes of morbidity and mortality in children in sub-Saharan Africa. Administration of three courses of sulfadoxine/pyrimethamine (SP) as intermittent preventive treatment (IPTi) to infants when they…
- Trial name
- NCT00158574
- Testing
- sulphadoxine-pyrimethamine, mefloquine, Chlorproguanil-dapsone
- Where
- Tanzania
- Volunteers
- 2,419 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Malaria
Intermittent Preventive Treatment (IPTc) and Home Based Management of Malaria (HMM)in The Gambia
Malaria in African countries remains an important cause of mortality and morbidity among young children. The global malaria control strategies include prompt treatment with an effective antimalarial drug, vector control using…
- Trial name
- NCT00944840
- Testing
- SP plus amodiaquine
- Where
- The Gambia
- Volunteers
- 1,312 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Malaria
Cost-effectiveness Evaluation of Vector Control Strategies in Mozambique
This study aims to provide National Malaria Control Programs (NMCP), international donors and other key stakeholders with clear evidence on the impact and cost-effectiveness of using indoor residual spraying (IRS) with a…
- Trial name
- COST (NCT02910934)
- Testing
- Actellic CS
- Where
- 2 sites in United States, Mozambique
- Volunteers
- 3,915 people, healthy volunteers welcome
- Sponsor
- PATH
Plasmodium Falciparum Infection
Safety and Immunogenicity of Sanaria's Irradiated Sporozoite Vaccine (PfSPZ Vaccine) in Malaria-Experienced Adults in Burkina Faso
This study is a phase 1, randomized, double-blind, placebo-controlled, dose escalation trial of Sanaria's irradiated sporozoite vaccine (PfSPZ vaccine).
- Trial name
- NCT02663700
- Testing
- Artesunate, PfSPZ Vaccine
- Where
- Burkina Faso
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria, Malaria Vaccines
Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa
This epidemiology study was conducted in parallel with the EPI-MAL-002 (NCT02374450) and EPI-MAL-003 (NCT03855995) studies, enrolling participants from the same health and demographic surveillance system (HDSS) (or equivalent…
- Trial name
- NCT02251704
- Testing
- Assessment of body temperature, Blood sampling
- Where
- 12 sites in Burkina Faso, Ghana and 4 more
- Volunteers
- 54,115 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria
Evaluation of the Protective Efficacy of a Vaccine Derived From the Synthetic CS Protein of Plasmodium Vivax
This is a randomized, double-blind, controlled, which seeks to compare two groups of volunteers (naive and previously exposed to malaria) who were made 3 immunizations with a synthetic derivative of the CS protein of Plasmodium…
- Trial name
- NCT02083068
- Testing
- Vaccine PvCS N+C+R, Vaccine PvCS N+C, SSN Montanide ISA-51
- Where
- Colombia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Malaria Vaccine and Drug Development Center
Malaria
Study to Assess the Vaccine Efficacy Against Malaria Infection, in Children Immunized With the Primary and Yearly Booster of the RTS,S/AS01E Vaccine, as Part of Their Participation in the Malaria-094 (204889/NCT03276962) Study.
The aim of this study was to evaluate the effectiveness of the RTS,S/AS01E malaria vaccine against both clinical and asymptomatic malaria infections by detecting Plasmodium falciparum (P.
- Trial name
- NCT03281291
- Where
- 2 sites in Ghana, Kenya
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria
Safety and Immunogenicity in Age De-Escalation of PfSPZ Vaccine in Tanzanian Adults, Children, and Infants
The present trial will evaluate safety and tolerability as well as the vaccine-induced humoral and cellular immune responses in healthy Tanzanian adults, adolescents, children, and infants who receive doses of 1.8x10^6, 9.0x10^5…
- Trial name
- NCT02613520
- Testing
- PfSPZ Vaccine, Normal Saline, PfSPZ Challenge (for CHMI)
- Where
- Tanzania
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Pharmacologic Action
Genetic Variability in CYP2D6 in U.S Active Duty Population
The investigator proposes to 2D6 (Cytochrome P-450 Isoenzyme 2D6) genotype and phenotype a group of active duty service members and assess the effects on primaquine metabolism.
- Trial name
- NCT02960568
- Testing
- Primaquine
- Where
- United States
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Walter Reed Army Institute of Research (WRAIR)
Plasmodium Falciparum Malaria
Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly
Malaria is an illness caused by a parasite (an animal or plant that lives in or on a host) that enters the human body through the bite of an infected mosquito.
- Trial name
- NCT00347555
- Testing
- Aluminum Phosphate, EBA-175 RII-NG Malaria Vaccine
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Study of Controlled Human Malaria Infections to Evaluate Protection After Intravenous or Intramuscular Administration of PfSPZ Vaccine in Malaria-Naive Adults
Background: People bitten by mosquitoes carrying weakened malaria parasites could fight off the disease if later exposed to normal malaria parasites.
- Trial name
- NCT02015091
- Testing
- PfSPZ Vaccine
- Where
- 2 sites in United States
- Volunteers
- 141 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
L9LS-R21 Interaction
This is a randomized, double-blind, placebo-controlled trial in 2 parts evaluating the effect of 1-time administration of the monoclonal antibody (MAb) L9LS to healthy Malian participants on the immunogenicity of subsequent…
- Trial name
- NCT07208760
- Testing
- Single dose of 1800 mg L9LS SC (12mL), Single dose of 225 mg L9LS SC (1.5mL)
- Where
- Mali
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Target Antigens Induced by Plasmodium Falciparum Sporozoite Immunization Under Chemoprophylaxis
Malaria, a disease caused by the parasite Plasmodium, is one of the world's major infectious diseases. With approximately 627.000 deaths a year, there is desperate need for an effective vaccine.
- Trial name
- BMGF1 (NCT02080026)
- Testing
- CPS-immunization, Controlled Human Malaria Infection, chloroquine
- Where
- Netherlands
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Malaria Diagnosis, Malaria,Falciparum
Evaluation of the Performance of a hsRDT Versus cRDT in Reactive Case Detection of Malaria Infections
A systematic review assessing the role, appropriateness and benefits of the active case detection strategy, both proactive and reactive, in low malaria transmission settings.
- Trial name
- NCT03511443
- Testing
- hsRDT
- Where
- Burma
- Volunteers
- 1,980 people, healthy volunteers welcome
- Sponsor
- University Research Co, LLC
Malaria
Age of Exposure and Immunity to Malaria in Infants
The overall objective is to evaluate the effect of exposure to Plasmodium (P.) falciparum erythrocytic stage antigens during different periods of infancy on the development of naturally acquired immunity (NAI).
- Trial name
- NCT00231452
- Testing
- Sulfadoxine-pyrimethamine (SP) + Artesunate (AS)
- Where
- Mozambique
- Volunteers
- 349 people, healthy volunteers welcome
- Sponsor
- Hospital Clinic of Barcelona
Malaria
Single-Blind, Placebo-Controlled, Randomized Study Testing Single Ascending Doses Of GSK369796 In Healthy Subjects
This study will examine safety of single doses of GSK369796 in healthy subjects, along with some test to examine how quickly GSK369796 gets in your blood, and how long it takes your body to get rid of it.
- Trial name
- NCT00675064
- Testing
- GSK369796
- Where
- United Kingdom
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria,Falciparum, Malaria
CHILD (Child Health and Infection With Low Density) Malaria
This trial will assess the long-term health and socioeconomic impact of interventions targeting low-density malaria infection (LMI) among children in Tanzania
- Trial name
- NCT05567016
- Testing
- Active case detection using molecular testing (ACDm), Passive case detection using molecular testing (PCDm), Control (standard of care)
- Where
- Tanzania
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Malaria
Dose Escalation PfSPZ-CVac
Background: People get malaria from bites from infected mosquitos. Researchers are studying a vaccine strategy. They will give people malaria parasites by injecting them with live infectious malaria parasites with antimalarial…
- Trial name
- NCT03083847
- Testing
- Chloroquine Phosphate, Pyrimethamine, Sanaria PfSPZ Challenge
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa
The purpose of this study is to conduct long-term surveillance for efficacy, safety and immunogenicity of the GSK Biologicals RTS,S/AS01E candidate Plasmodium falciparum malaria vaccine in infants and children in Africa following…
- Trial name
- NCT02207816
- Testing
- Blood sampling, Malaria Vaccine 257049 (MALARIA-055 PRI), Meningococcal C Conjugate Vaccine (MALARIA-055 PRI)
- Where
- 3 sites in Burkina Faso, Kenya and 1 more
- Volunteers
- 3,084 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria (Plasmodium Falciparum), Malaria Falciparum
Safety and PK of MMV371 LAI in Healthy Adults and Adolescents in Rwanda
This Phase 1b study will assess the safety, tolerability and pharmacokinetics (PK, this measures the levels of study drug in the body) of a single injection of MMV371 in healthy adult and adolescent participants in Rwanda.
- Conditions
- Malaria (Plasmodium Falciparum), Malaria Falciparum, Malaria Infection, Malaria Prophylaxis
- Trial name
- NCT07548021
- Testing
- MMV371
- Where
- Rwanda
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture